A Safety Study of SGN-CD19A for B-Cell Lymphoma
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and
 tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin
 lymphoma (B-NHL)
Inclusion Criteria:

 -  Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade
 3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology,
 Burkitt lymphoma, or B-lineage lymphoblastic lymphoma

 -  Relapsed, refractory, or progressive disease following at least 1 prior systemic
 therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received
 intensive salvage therapy.

 -  Eastern Cooperative Oncology Group status of 0 or 1

 -  Measurable disease

 Exclusion Criteria:

 -  Allogeneic stem cell transplant (SCT)